BRPI0510778A - composição farmacêutica, processo para a preparação da mesma, método para o tratamento de rinite, e, uso de uma composição - Google Patents

composição farmacêutica, processo para a preparação da mesma, método para o tratamento de rinite, e, uso de uma composição

Info

Publication number
BRPI0510778A
BRPI0510778A BRPI0510778-4A BRPI0510778A BRPI0510778A BR PI0510778 A BRPI0510778 A BR PI0510778A BR PI0510778 A BRPI0510778 A BR PI0510778A BR PI0510778 A BRPI0510778 A BR PI0510778A
Authority
BR
Brazil
Prior art keywords
composition
preparing
treating rhinitis
pharmaceutical composition
rhinitis
Prior art date
Application number
BRPI0510778-4A
Other languages
English (en)
Inventor
Lena Pereswetoff-Morath
Anders Carlsson
Original Assignee
Biolipox Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolipox Ab filed Critical Biolipox Ab
Publication of BRPI0510778A publication Critical patent/BRPI0510778A/pt
Publication of BRPI0510778B1 publication Critical patent/BRPI0510778B1/pt
Publication of BRPI0510778B8 publication Critical patent/BRPI0510778B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIçãO FARMACêUTICA, PROCESSO PARA A PREPARAçãO DA MESMA, MéTODO PARA O TRATAMENTO DE RINITE, E, USO DE UMA COMPOSIçãO São fornecidas composições farmacêuticas para o tratamento de rinite, por exemplo, pela administração nasal ou ocular que compreende cetirizina zuiteriónica, um lipossoma lipídico polar e um veículo aquoso farmaceuticamente aceitável. As composições são preferivelmente homogêneas em sua natureza.
BRPI0510778A 2004-05-11 2005-05-06 composição farmacêutica, processo para preparação da :mesma, e, uso de uma composição BRPI0510778B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/842433 2004-05-11
US10/842,433 US20050255154A1 (en) 2004-05-11 2004-05-11 Method and composition for treating rhinitis
PCT/GB2005/001758 WO2005107711A2 (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis

Publications (3)

Publication Number Publication Date
BRPI0510778A true BRPI0510778A (pt) 2007-11-20
BRPI0510778B1 BRPI0510778B1 (pt) 2020-03-10
BRPI0510778B8 BRPI0510778B8 (pt) 2021-05-25

Family

ID=34968224

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510778A BRPI0510778B8 (pt) 2004-05-11 2005-05-06 composição farmacêutica, processo para preparação da :mesma, e, uso de uma composição

Country Status (24)

Country Link
US (3) US20050255154A1 (pt)
EP (1) EP1771155B1 (pt)
JP (1) JP4976283B2 (pt)
CN (2) CN103271910B (pt)
AT (1) ATE550015T1 (pt)
AU (1) AU2005239866B2 (pt)
BR (1) BRPI0510778B8 (pt)
CA (1) CA2536728C (pt)
CY (1) CY1112981T1 (pt)
DK (1) DK1771155T3 (pt)
EA (1) EA014752B1 (pt)
ES (1) ES2395130T3 (pt)
HR (1) HRP20120484T1 (pt)
IL (1) IL179012A (pt)
ME (1) ME01436B (pt)
MX (1) MXPA06013121A (pt)
NO (1) NO335840B1 (pt)
NZ (1) NZ550412A (pt)
PL (1) PL1771155T3 (pt)
PT (1) PT1771155E (pt)
RS (1) RS52311B (pt)
SI (1) SI1771155T1 (pt)
WO (1) WO2005107711A2 (pt)
ZA (1) ZA200608407B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060484A1 (es) 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
PL1888033T3 (pl) 2005-06-09 2014-09-30 Meda Ab Sposób i kompozycja do leczenia chorób zapalnych
FR2900576B1 (fr) * 2006-05-03 2008-09-19 Centre Nat Rech Scient Procede de concentration extemporanee et reversible de liposomes.
WO2007144902A1 (en) * 2006-06-12 2007-12-21 Jubliant Organosys Limited Chewable bilayer tablet formulation
CA2705530A1 (en) 2007-11-16 2009-05-28 Baylor College Of Medicine Phospholipid compositions and uses thereof
WO2009148955A2 (en) * 2008-05-29 2009-12-10 Mdrna, Inc Multi-arm amines and uses thereof
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
EP2408453B1 (en) 2009-03-17 2022-01-05 Nicox Ophthalmics, Inc. Ophthalmic formulations of cetirizine and methods of use
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8524692B2 (en) * 2010-04-29 2013-09-03 Georgia Health Sciences University Research Institute, Inc. Ocular compositions containing dioleoylphosphatidylglycerol and uses thereof
JP2013535456A (ja) * 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
CN102525921B (zh) 2012-02-06 2013-08-07 西安力邦制药有限公司 2,2’,6,6’-四异丙基-4,4’-二联苯酚脂微球制剂及其制备方法
KR101475776B1 (ko) * 2012-08-24 2014-12-24 영진약품공업 주식회사 이중 포화 인지질을 포함하는 안정한 피부 외용 조성물
CN104887635B (zh) * 2015-05-20 2019-06-11 苏州东瑞制药有限公司 一种盐酸西替利嗪片及其制备工艺
CN113434592A (zh) 2018-10-31 2021-09-24 创新先进技术有限公司 基于区块链的数据存证方法及装置、电子设备
CA3157107A1 (en) * 2019-11-04 2021-05-14 Manuel Valiente Malmagro Tooth whitening composition
CN114392235B (zh) * 2022-01-28 2023-06-27 成都大学 盐酸西替利嗪眼用脂质体、原位凝胶及其制备方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
GB8522964D0 (en) 1985-09-17 1985-10-23 Biocompatibles Ltd Aerosol
EP0249561B1 (en) 1986-06-12 1992-05-13 The Liposome Company, Inc. Compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
WO1987007506A1 (en) 1986-06-12 1987-12-17 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
US4839175A (en) * 1986-07-28 1989-06-13 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
SE8603812D0 (sv) 1986-09-12 1986-09-12 Draco Ab Administration of liposomes to mammals
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
EP0472639A4 (en) 1989-05-15 1992-07-01 The Liposome Company, Inc. Accumulation of drugs into liposomes by a proton gradient
US5498420A (en) * 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
CA2120197A1 (en) * 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
AU686277B2 (en) * 1993-11-16 1998-02-05 Pacira Pharmaceuticals, Inc. Vesicles with controlled release of actives
DE4341472A1 (de) 1993-12-02 1995-06-08 Schering Ag Verfahren zur Erhöhung der Stabilität von hydrophile Wirkstoffe enthaltenden Liposomensuspensionen
CN1083713C (zh) * 1994-02-04 2002-05-01 利珀克尔集团公司 双层制剂
US6773719B2 (en) * 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
PL183552B1 (pl) * 1994-09-23 2002-06-28 Axys Pharmaceuticals Nowe związki cykliczne i środek farmaceutyczny
WO1997001337A1 (en) 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
US5783566A (en) * 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
AU3153797A (en) 1996-06-04 1998-01-05 Procter & Gamble Company, The A nasal spray containing an intranasal steroid and an antihistamine
TW497974B (en) 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
US5958378A (en) 1996-07-03 1999-09-28 Research Development Foundation High dose liposomal aerosol formulations containing cyclosporin A or budesonide
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
WO1998048839A1 (en) 1997-04-30 1998-11-05 Warner-Lambert Company Topical nasal antiinflammatory compositions
GB2326337A (en) 1997-06-20 1998-12-23 Phares Pharma Holland Homogeneous lipid compositions for drug delivery
JP2002507917A (ja) * 1997-07-04 2002-03-12 トルサナ オステオポロシス ダイアグノスティクス アクティーゼルスカブ 脊椎動物の骨質又は骨格状態を評価するための方法
DE69825495T2 (de) * 1998-12-23 2005-07-28 Idea Ag Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
GR1003359B (el) 1998-12-24 2000-04-10 �.�. ����������� �.�.�.�. Λιποσωμιακο νιφλουμικο οξυ - νεο διαδερμικο αντιφλεγμονωδες φαρμακο [κεφαλη ψαροτουφεκου
US6613352B2 (en) * 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
WO2001082892A2 (de) * 2000-05-02 2001-11-08 Pharmacept Gmbh Wirkstoffhaltige liposome
DK1347743T3 (da) 2000-12-07 2006-07-03 Univ Utrecht Holding Bv Præparat til behandling af inflammatoriske lidelser
US20030144336A1 (en) * 2001-08-27 2003-07-31 Pfizer Inc. Method of selecting nonsedating H1-antagonists
US20030054030A1 (en) * 2001-09-13 2003-03-20 Gary Gordon Method and compositions for the treatment of pruritus
KR20050044550A (ko) 2001-12-05 2005-05-12 알콘, 인코퍼레이티드 비염 치료를 위한 η1 길항제 및 안전한 스테로이드제의용도
WO2003097100A1 (en) 2002-05-15 2003-11-27 Engelbrecht, Edna Topical composition for the treatment of inflammatory conditions of the skin
EP1371362A1 (en) 2002-06-12 2003-12-17 Universiteit Utrecht Holding B.V. Composition for treatment of inflammatory disorders
US20040192601A1 (en) * 2002-08-02 2004-09-30 Silvia Corvera Lipid binding molecules and methods of use
JP2004168709A (ja) * 2002-11-20 2004-06-17 Nidek Co Ltd 抗アレルギー点眼点鼻用組成物
WO2004069338A1 (en) * 2003-01-31 2004-08-19 Schering Corporation Use of combinations of h1 and h3 histamine receptor antagonists for the preparation of a medicament for the treatment of allergic skin and allergic ocular conditions
US20050112199A1 (en) * 2003-09-24 2005-05-26 Mahesh Padval Therapeutic regimens for administering drug combinations
WO2005039533A1 (en) 2003-10-15 2005-05-06 Medigene Ag Method of administering cationic liposomes comprising an active drug
JP2005170923A (ja) * 2003-10-21 2005-06-30 Konica Minolta Medical & Graphic Inc リポソーム含有ｘ線造影剤およびその製造方法

Also Published As

Publication number Publication date
IL179012A (en) 2014-11-30
MXPA06013121A (es) 2007-05-16
EP1771155A2 (en) 2007-04-11
EA014752B1 (ru) 2011-02-28
WO2005107711A3 (en) 2006-03-16
US20180104238A9 (en) 2018-04-19
CA2536728A1 (en) 2005-11-17
AU2005239866A1 (en) 2005-11-17
ZA200608407B (en) 2007-12-27
NZ550412A (en) 2010-08-27
BRPI0510778B8 (pt) 2021-05-25
CN103271910B (zh) 2018-11-06
US20050255154A1 (en) 2005-11-17
CA2536728C (en) 2011-02-01
US20070026058A1 (en) 2007-02-01
CY1112981T1 (el) 2016-04-13
ES2395130T3 (es) 2013-02-08
HK1098960A1 (en) 2007-08-03
EA200602092A1 (ru) 2007-06-29
ATE550015T1 (de) 2012-04-15
PT1771155E (pt) 2012-05-15
US9980959B2 (en) 2018-05-29
ME01436B (me) 2012-12-31
CN1984643A (zh) 2007-06-20
PL1771155T3 (pl) 2012-08-31
EP1771155B1 (en) 2012-03-21
JP2007537220A (ja) 2007-12-20
DK1771155T3 (da) 2012-07-09
NO335840B1 (no) 2015-03-02
JP4976283B2 (ja) 2012-07-18
RS52311B (sr) 2012-12-31
HRP20120484T1 (hr) 2012-07-31
NO20064521L (no) 2007-02-06
AU2005239866B2 (en) 2010-03-04
SI1771155T1 (sl) 2012-09-28
CN103271910A (zh) 2013-09-04
US20130039969A1 (en) 2013-02-14
IL179012A0 (en) 2007-03-08
WO2005107711A2 (en) 2005-11-17
BRPI0510778B1 (pt) 2020-03-10

Similar Documents

Publication Publication Date Title
CY1112981T1 (el) Μεθοδος και συνθεση για την αγωγη της ρινιτιδας
BRPI0416801A (pt) derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
DE602006006308D1 (de) Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten
BRPI0416796A (pt) compostos orgánicos
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
CY1116075T1 (el) Νεες συνθεσεις λιποσωματων
BRPI0412404A (pt) uso de rapamicina e de derivado da rapamicina para o tratamento da perda óssea
BRPI0517634A (pt) derivado de tiazol ou um derivado farmaceuticamente aceitável do mesmo, processo para a preparação de um composto, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
NO20075660L (no) Blanding for behandling av inflammatoriske sykdommer
BR112012006252A2 (pt) "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
CY1108676T1 (el) Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων
GEP20094781B (en) Sulfonamide derivatives for the treatment of diseases
BRPI1010861A8 (pt) métodos para tratamento de dor, inflamação ou osteoartrite, pacote e formulação farmacêutica
DK2170857T3 (da) 3',4',5-trimethoxyflavonderivater som stimulerende middel ved slimafsondring, tilsvarende fremgangsmåde og farmaceutisk præparat, der indeholder disse
NO20092763L (no) Isosorbid mononitrat derivater for behandling av tarmlidelser
MX2007010295A (es) Composiciones oftalmologicas novedosas y metodo para su uso.
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей
NO20061236L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og paratyroidhoziiton
BR0316123A (pt) Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico
AR059581A1 (es) Procedimientos para el tratamiento de degeneracion macular y afecciones oculares relacionadas
NO20060655L (no) 2-alkyliden-19-Nor-vitamin D derivater for behandling av osteofeni eller osteoporose hos hannkjonn
CL2012000172A1 (es) Compuestos derivados de heterociclos nitrogenados, reductores de peptido beta-amiloide; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades de alzheimer, sindrome de down, alteracion cognitiva debil, degeneracion macular relacionada con la edad.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/05/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2773 DE 27-02-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.